Introduction: Assessment of systemic inflammatory response forms the basis of several scoring systems that attempt to prognosticate patients with periampullary pancreatic carcinoma (PPC). We assessed the validity of three of these scoring systems for patients' prognosis following intervention for PPC: Glasgow prognostic score (GPS) and its modified version (mGPS), platelet-lymphocyte ratio (PLR) and neutrophil-lymphocyte ratio (NLR).
Introduction
Periampullary pancreatic cancer (PPC) has an overall 5-year survival varying from 36 to 51%, with a median survival of 66 months in patients who undergo resection. [1] [2] [3] Surgical resection is the only curative treatment for such cancers; however, resection is only possible in 15-20% of patients. [3] The mainstay of surgical resection is in the form of either pylorus-preserving pancreaticoduodenectomy (PPPD) or Kausch-Whipple's procedure. Both PPPD and KauschWhipple's procedure have a reported perioperative morbidity of approximately 40% [4] and a reported mortality of 3% in high volume specialised centres. [5] Improved patient selection, better imaging techniques and the introduction of adjuvant chemotherapy have improved patients' outcomes in recent years. However, tumour behaviour remains difficult to assess preoperatively with only detailed post-operative histological examination allowing meaningful prognostic factors, such as lymph node status, histological subtype, tumour stage and margin status, to be fully defined.
There is thus a need for robust markers or biomarkers that could be used in the prognostic stratification of patients with PPC before surgical resection.
Scoring systems based on the assessment of the systemic inflammatory response have been shown to be useful preintervention indicators of prognosis in various neoplastic conditions. [6] [7] [8] Glasgow prognostic score (GPS), including its modified version (mGPS), the platelet-lymphocyte ratio (PLR) and the neutrophil-lymphocyte ratio (NLR). However, none of them have been adopted routinely into clinical practice and few have been externally validated. The role of these scoring systems in patients with PPC remains unexplored.
The aim of this review was to evaluate the evidence for the prognostic value of these scoring systems in predicting outcomes in patients with PPC, specifically assessing the ability to predict patient survival.
Materials and Methods
A literature search was performed to identify all studies that examined the prognostic value of one or more of the three scoring systems in patients with PPC. All studies published from 1966 to 1 st week September 2018 were evaluated. EMBASE and MEDLINE databases were searched using comprehensive text and MeSH terms. Keywords used for search are listed as under (periampullary cancer*, periampullary carcinoma*, periampullary tumours*, periampullary adenocarcinoma*, GPS*, modified GPS*, GPS* or mGPS*, PLR*, PLR*, NLR* and NLR*). Google Scholar was used to identify additional manuscripts. A bibliography of included articles was hand searched for relevant additions. Two investigators independently searched and analysed all data, and consensus was sought with a third author where discrepancies existed.
Since all studies were observational, our search protocol was based on meta-analysis of observational studies in epidemiology guidelines. [9] All papers indexed in the English language were included. Case reports or case series, unpublished abstracts, proceedings of meetings and animal studies were excluded. After removal of duplicates and irrelevant articles, abstracts were screened for further exclusions. Full-text articles were then read before inclusion in the analysis. Assessment of bias in the studies was made using the risk of bias in nonrandomised studies of interventions (ROBINS-I) tool by two reviewers independently. The ROBINS-I tool assesses bias across six domains including confounding, participant selection, intervention classification, departure from intended interventions, missing data, measurement of outcomes and selection of reported results. For each domain, an outcome of low, moderate, serious, critical and no information for risk of bias is recorded. An overall risk of bias judgement is then determined through combination of the six domains.
The primary aim of our review was to assess if any of these scoring systems could be used to predict patient outcome in PPC.
Results
The results from searching the EMBASE and MEDLINE databases are presented in Table 1 . Among the included studies, one focused on the prognostic value of GPS, two assessed NLR and three investigated the value of PLR in PC.
Three studies evaluated GPS in patients with PPC periods. [10, 11] Garcea et al. described 137 patients with potentially resectable PPC lesions detected on preoperative imaging who were assessed for resectability at laparoscopy. Five patients had PPC in this series. Patient outcome after surgical intervention was not reported. GPS was assessed to see if it could be used to discriminate operability before laparoscopy, but no statistical difference was found. [10] Lowe et al. assessed that 302 patients had pancreatic resection for periampullary cancers, of which 45 had histologically confirmed PPC and 96% had an R0 resection. The data presented in this study did not allow for calculation of the GPS, and hence, this could not be assessed in the presented review. Kumamoto et al. assessed 84 patients and found that the GPS did not accurately predict postoperative major complications. [12] Four studies evaluated NLR in patients with PPC. [10, [12] [13] [14] Garcea et al. demonstrated that NLR has no pre-operative value in discriminating between operable and non-operable disease and has no value in detecting occult disease. [10] Kumamoto et al. found that a higher NLR as associated with major complications. [12] Hamed et al. evaluated the use of NLR in 74 patients with periampullary tumours; they demonstrated that the median survival between patients having NLR >5 and <5 was not significantly different; however, in patients developing recurrence, NLR <5 was associated with improved survival. [13] Demirci et al. found that an NLR of more than 3 was associated with overall survival and disease-free survival. [14] Three studies aimed to assess the role of PLR in patients with PC. [10, [15] [16] [17] Garcea et al. showed no role of PLR in assessing the benefit of staging laparoscopy in PPC patients. Smith et al. included 263 pancreatic resections in their study, of which 48 had PPC. The authors demonstrated that pre-operative median PLR pf < or=150 was significantly associated with locally advanced and metastatic disease in patients with periampullary lesions (P < 0.001), but this group included pancreatic ductal adenocarcinoma, cholangiocarcinoma and metastatic adenocarcinoma. Overall patient survival was not presented in this study although median PLR was specifically associated with increased risk of nodal disease in patients with PC (P = 0.002). Demirci et al. assessed 82 patients with PPC and found that a PLR >212 was associated with a significantly worse overall survival. [17] The limited data and heterogeneity of the studies were such that a meta-analysis was not possible and only a descriptive analysis of the studies was made.
Discussion
Patient outcome following surgical intervention for PPC depends on both tumour biology and patientrelated factors. The systemic inflammatory response is acknowledged to be an important factor in many tumours including PPC. [18] The mechanism of PPC development remains incompletely understood and is likely to involve chronic inflammation, immune cell activation and growthpromoting signalling pathways. [19] The inflammatory response may serve as a potential parameter to help prognosis stratification with the aim to improve patient's outcome.
In this review, we assessed elements of the inflammatory response evaluating the GPS, NLR and PLR scoring systems to investigate whether they can be helpful tools in patients' stratification and, in particular, if they could predict resectability. [7, 20] These scoring systems may allow pre-operative identification of aggressive tumours, thus changing the treatment strategy (e.g., neoadjuvant treatments) and provide individualised care. If reliable, they could also serve as useful monitoring tools after successful resection.
Many cancers have been shown to incite a systemic inflammatory response as evidenced by an elevated C-reactive protein (CRP). Indeed, a recent study by Shirai et al. has shown that in patients with pancreatic ductal cancer that demonstrates a significant inflammatory response have a poorer prognosis and poorer survival. [21] The fine mechanisms of these events remain elusive, but the release of pro-inflammatory cytokines such as tumour necrosis factor α and interleukin-6, modulation of endothelial cell function and angiogenesis seems to play a significant role. [22] REVIEW ARTICLE J Cancer Allied Spec 2019;5(2):2 GPS provides an objective scoring system that combines CRP and serum albumin. [23] There are reports of adverse outcomes in patients with hepatobiliary malignancy and elevated GPS. [24] Only one study was found which investigated the potential role of GPS in PPC, and unfortunately, this only assessed whether the scoring system could discriminate between patients with operable and non-operable disease. Therefore, it remains to be established if GPS or mGPS can be used as a pre-operative scoring system. NLR is calculated from the differential count by dividing the absolute neutrophil count with the absolute lymphocyte count. NLR >5 is considered significant and a poor prognostic marker. [25] However, no study has clearly assessed the role NLR in predicting patient survival following a diagnosis of PPC. Although one study in our review did suggest that patients with NLR >5 were associated with inferior patient outcome in periampullary tumours when PPC was assessed, NLR was found not to be predictive. [13] It remains to be established if NLR could represent a useful tool in the pre-operative work-up in patients with PPC.
PLR is calculated in a similar manner as NLR but with the substitution of platelets for neutrophil count. There is some degree of discrepancy in defining a significant PLR; however, most studies stratified patients into three groups with a PLR <150, PLR 150-300 and PLR >300 indicating good, moderate and poor prognosis, respectively. [26] In our review, we found that two studies were from the same unit and covered the same study period. Hence, these data need to be interpreted carefully. The available literature does not allow for any firm conclusion as to the utility of PLR in patients with PPC. It is possible that PLR may be associated with poorer patient outcome, but it was not statistically significant.
It is important to note that the quality of the studies available for this meta-analysis was of low quality [ Table 2 ] with many studies being retrospective and in some cases with low numbers of patient with PPC [ Table 3 ].
Conclusion
There is a lack of evidence within literature regarding the prognostic use of inflammatory scoring systems in PPC. In addition, the available studies are of low quality with heterogeneous patient cohorts, low numbers and are retrospective in nature. Further research and larger studies are needed before recommending these scoring systems in patients with PPC.
